As of Sep 26
| -0.31 / -1.18%|
The 7 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 27.00, with a high estimate of 37.00 and a low estimate of 24.00. The median estimate represents a +4.41% increase from the last price of 25.86.
The current consensus among 7 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.